Business Description
Korro Bio Inc
NAICS : 541714
SIC : 2833
ISIN : US5009461089
Total Employee Number:
49Description
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.66 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.54 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -2.42 | |||||
Beneish M-Score | -3.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.8 | |||||
3-Year EPS without NRI Growth Rate | -9.7 | |||||
3-Year FCF Growth Rate | -4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.48 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.15 | |||||
9-Day RSI | 50.03 | |||||
14-Day RSI | 52.93 | |||||
3-1 Month Momentum % | -15.19 | |||||
6-1 Month Momentum % | 29.14 | |||||
12-1 Month Momentum % | -8.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.13 | |||||
Quick Ratio | 8.13 | |||||
Cash Ratio | 7.71 | |||||
Days Sales Outstanding | 123.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | -42.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2154.03 | |||||
Net Margin % | -2954.14 | |||||
EBITDA Margin % | -2064.63 | |||||
FCF Margin % | -1837.66 | |||||
OCF Margin % | -1826.73 | |||||
ROE % | -108.27 | |||||
ROA % | -67.45 | |||||
ROIC % | -116.41 | |||||
3-Year ROIIC % | -182.78 | |||||
ROC (Joel Greenblatt) % | -231.38 | |||||
ROCE % | -53.75 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.1 | |||||
PB Ratio | 1.63 | |||||
Price-to-Tangible-Book | 1.63 | |||||
EV-to-EBIT | -1.49 | |||||
EV-to-EBITDA | -1.56 | |||||
EV-to-Revenue | 32.18 | |||||
EV-to-Forward-Revenue | 41.15 | |||||
EV-to-FCF | -1.75 | |||||
| Price-to-Net-Current-Asset-Value | 3.47 | |||||
| Price-to-Net-Cash | 3.89 | |||||
Earnings Yield (Greenblatt) % | -67.11 | |||||
FCF Yield % | -36.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KRRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Korro Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.842 | ||
| EPS (TTM) ($) | -11.67 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 168.69 | ||
| 14-Day RSI | 52.93 | ||
| 14-Day ATR ($) | 1.222689 | ||
| 20-Day SMA ($) | 13.19325 | ||
| 12-1 Month Momentum % | -8.65 | ||
| 52-Week Range ($) | 5.2044 - 55.89 | ||
| Shares Outstanding (Mil) | 14.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Korro Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Korro Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 29 days | ||
| General meeting for 2026 | 2026-06-10 08:30 | 10.94 (+1.48%) | ||
| Guidance call for 2026 | 2026-06-04 16:20 | 11.08 (-0.36%) | ||
| Guidance call for 2026 | 2026-05-20 11:30 | 9.15 (-7.76%) | ||
| HCW 4th Annual BioConnect Nasdaq Investor Conference | 2026-05-19 16:00 | 9.97 (-3.02%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 13.34 (+4.87%) | ||
| Annual report for 2025 | 2026-03-12 | 11.76 (+2.89%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 11.76 (+2.89%) | ||
| TD Cowen 46(th) Annual Health Care Conference | 2026-03-03 11:10 | 11.50 (+0.17%) |
Show
Entries
Korro Bio Inc Frequently Asked Questions
What is Korro Bio Inc(KRRO)'s stock price today?
The current price of KRRO is $13.49. The 52 week high of KRRO is $55.89 and 52 week low is $5.20.
When is next earnings date of Korro Bio Inc(KRRO)?
The next earnings date of Korro Bio Inc(KRRO) is 2026-08-12 Est..
Does Korro Bio Inc(KRRO) pay dividends? If so, how much?
Korro Bio Inc(KRRO) does not pay dividend.
Guru Commentaries on NAS:KRRO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Korro Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers